Q-omics provides the consensus-scored UBL4A profile across patient tissues and cancer cell-line models. UBL4A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UBL4A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, UBL4A RNA expression shows 18,258 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where UBL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBL4A survival associations across molecular data types. UBL4A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBL4A RNA expression–survival associations across cancer types. High UBL4A expression shows unfavorable associations in KICH, UVM, LGG, LIHC, PAAD and LAML. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for UBL4A RNA expression.
This table summarizes UBL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBL4A shows higher tumor expression in HNSC, KIRC, COAD, LIHC, LUAD and KIRP. The HNSC box plot shows higher UBL4A RNA expression in tumor versus normal tissue (log2 FC = +1.036, t-test p < 0.001).
This table shows molecular features associated with UBL4A in patient tissues and cancer cell lines. In patient samples, UBL4A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
